samedan logo
 
 
 
spacer
home > pmps > winter 2003 > new developments in the containment of pharmaceutical powders
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

New Developments in the Containment of Pharmaceutical Powders

There is a growing trend for routine day-to-day pharmaceutical powder processing and production operations to involve 'high potency' powders. To meet this challenge new strategies for powder handling are being developed along with engineering advances in the equipment used to contain the active or high potency materials. The term 'containment', of course, refers to the isolation of hazardous materials (high potency) using engineering methods in various guises. Containment can protect the operator from the compound or protect the compound from operator-borne containment. In some cases specialised containment devices protect the operator from the materials and vice versa.

First of all it is important to appreciate the growth of high potency compounds within the pharmaceutical industry. In 1990, only about five per cent of all pharmaceutical actives handled were considered potent. Now in the year 2001, over 30 per cent of all APIs are classified as 'potent', and therefore require special attention to protect the operator from the effects of coming into contact with these materials.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Martyn Ryder, Director of Extract Technology, part of the Carlisle Sciences Group

Martyn Ryder, Vice President of Business Development at Carlisle Life Sciences Europe, was educated at Leeds Polytechnic in HVAC and Building Services. In 1981 he founded Extract Technology, a company which has grown to be one of the world's leading suppliers of pharmaceutical dust control and high containment systems. The company is now part of the Carlisle Life Sciences Group, a division of Carlisle Corporation, a diversified global manufacturing company, serving the transportation, construction, commercial roofing, automotive, food service, data transmission and pharmaceutical and biotech industries.

spacer
Martyn Ryder
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Cidara Therapeutics Doses First Patient in Pivotal Phase 3 ReSPECT Trial of Rezafungin for Prevention of Invasive Fungal Disease in Patients Undergoing Allogeneic Blood and Marrow Transplantation

SAN DIEGO, Calif. & CAMBRIDGE, England, May 20, 2020 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, and Mundipharma today announced that the first patient has been dosed in its ReSPECT pivotal Phase 3 clinical trial evaluating the efficacy and safety of the company’s lead antifungal candidate, rezafungin, for the prevention of invasive fungal disease in patients undergoing allogeneic blood and marrow transplantation (BMT). Rezafungin is a novel, once-weekly echinocandin being developed for both the treatment and prevention of severe fungal infections.
More info >>

White Papers

Migration safe pharmaceutical labels improve patient safety

UPM Raflatac

Labels play an invaluable role on pharmaceutical packages. Pharmaceutical companies should only use labels that meet low-leachability and extraction requirements. Labels that are not migration safe, e.g. create leachable chemical compounds, may fail testing and result in significant launch delays or costly recalls. This white paper presents how pharmaceutical companies can ensure that the final label constructions achieve their business, regulatory and patient safety goals.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement